Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 213 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Prednisolone (Corticosteroid) Clear all
Recruiting Phase 2 Interventional

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

NCT06317662
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Interventions
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Leucovorin, Levoleucovorin, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Prednisolone, Prednisone, Therapeutic Hydrocortisone, Thioguanine, Venetoclax, Vincristine
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 365 Days
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
115
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 6, 2026, 10:46 PM EDT
Suspended Phase 1Phase 2 Interventional

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

NCT05789589
View directory record Official record
Conditions
Cancer, Metastasis, Metastatic Cancer, Brain Metastases, Brain Metastases, Adult
Interventions
Azeliragon, Stereotactic radiosurgery, Corticosteroid
Drug · Radiation
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 6, 2026, 10:46 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

NCT05067140
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
ARV-766, Abiraterone, Corticosteroid (e.g., prednisone/prednisolone), Androgen Deprivation Therapy (ADT)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
17
States / cities
Duarte, California • La Jolla, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 6, 2026, 10:46 PM EDT
Recruiting Phase 4 Interventional

Depo-Medrol on Psoas After LLIF

NCT05929755
View directory record Official record
Conditions
Muscle Weakness, Pain, Postoperative, Paresthesia, Pain, Muscle
Interventions
Depo-Medrol, Gel-Flow NT
Drug
Lead sponsor
Hardeep Singh
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 6, 2026, 10:46 PM EDT
Not yet recruiting Phase 4 Interventional

OMT for Adhesive Capsulitis

NCT07497737
View directory record Official record
Conditions
Adhesive Capsulitis of the Shoulder, Frozen Shoulder
Interventions
Intra-articular Injection, Osteopathic Manipulative Therapy (OMT)
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Beachwood, Ohio • Westlake, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 6, 2026, 10:46 PM EDT
Terminated Phase 2 Interventional Results available

Belatacept to Prevent Organ Rejection in Kidney Transplant Patients

NCT00346151
View directory record Official record
Conditions
Renal Transplant
Interventions
Belatacept, Sirolimus, Anti-thymocyte globulin, methylprednisolone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 6, 2026, 10:46 PM EDT
Completed Phase 1 Interventional Results available

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

NCT03792256
View directory record Official record
Conditions
Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma, T-cell Leukemia, Recurrent Disease, Acute Leukemia
Interventions
Palbociclib, Cytarabine, Methotrexate, Hydrocortisone, Doxorubicin, Prednisolone, Vincristine, Pegaspargase, Prednisone
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 31 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Loma Linda, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 6, 2026, 10:46 PM EDT
Terminated Phase 4 Interventional Results available

Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery

NCT04200651
View directory record Official record
Conditions
Glaucoma, Cataract
Interventions
Dexamethasone Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
The New York Eye Surgery Center
Other
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 6, 2026, 10:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations

NCT01266317
View directory record Official record
Conditions
IPF
Interventions
Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids
Drug
Lead sponsor
Michael Donahoe
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 6, 2026, 10:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

NCT02348216
View directory record Official record
Conditions
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
Interventions
Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
Gilbert, Arizona • Duarte, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 6, 2026, 10:46 PM EDT
Completed Phase 3 Interventional Results available

Corticosteroids for Children With Febrile Urinary Tract Infections

NCT01391793
View directory record Official record
Conditions
Acute Urinary Tract Infection, Urinary Tract Infection
Interventions
Placebo, Dexamethasone
Drug
Lead sponsor
Nader Shaikh
Other
Eligibility
2 Months to 6 Years
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Columbus, Ohio • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 6, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

NCT00035555
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation, Renal Transplantation
Interventions
Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
12
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 6, 2026, 10:46 PM EDT
Completed Not applicable Interventional Results available

The Effect of Glaucoma Drops on of the Duration of a Pure Intraocular Gas Bubble

NCT01843920
View directory record Official record
Conditions
Scleral Buckling
Interventions
Timolol-dorzolamide (Glaucoma drops), standard post-operative topical drops
Drug
Lead sponsor
Jason Hsu, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 6, 2026, 10:46 PM EDT
Completed Phase 4 Interventional

Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection

NCT00885820
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Tacrolimus, MMF, Corticosteroids (Prednisone)
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 6, 2026, 10:46 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.

NCT01272635
View directory record Official record
Conditions
Asthma, Wheezing
Interventions
Azithromycin, Prednisolone, Placebo Azithromycin, Placebo Prednisolone
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Months to 71 Months
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
16
States / cities
Tucson, Arizona • Oakland, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 6, 2026, 10:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

NCT07287397
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone
Genetic · Drug
Lead sponsor
Vector Y Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 6, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT01497496
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
High Dose Methylprednisolone (HDMP), Ofatumumab, Lenalidomide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 6, 2026, 10:46 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Autologous Transplant To End NMO Spectrum Disorder

NCT03829566
View directory record Official record
Conditions
Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder
Interventions
Rituximab, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 6, 2026, 10:46 PM EDT
Withdrawn Not applicable Interventional

Steroids Helping Albuterol Responders Exclusively

NCT00798616
View directory record Official record
Conditions
Bronchiolitis
Interventions
prednisolone or methylprednisolone, placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
4 Weeks to 24 Months
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 6, 2026, 10:46 PM EDT
Completed Phase 3 Interventional Results available

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729606
View directory record Official record
Conditions
Covid19
Interventions
Aviptadil, Aviptadil Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 6, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

NCT02614612
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Itacitinib (200 mg), Itacitinib (300 mg), prednisone or methylprednisolone (corticosteroids)
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 6, 2026, 10:46 PM EDT
Recruiting Not applicable Interventional

Efficacy of Intra-articular Injections for the Treatment of Primary Glenohumeral Osteoarthritis(GHOA)

NCT04949087
View directory record Official record
Conditions
Arthritis Shoulder
Interventions
Glenohumeral Injection
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 6, 2026, 10:46 PM EDT
Active, not recruiting Phase 3 Interventional

Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

NCT05345171
View directory record Official record
Conditions
OTC Deficiency
Interventions
DTX301, Placebo, Oral Corticosteroids, Placebo for oral corticosteroids, Sodium Acetate
Genetic · Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
12 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 6, 2026, 10:46 PM EDT
Terminated Phase 2 Interventional

Steroid Withdrawal in Pediatric Kidney Transplant Recipients

NCT00023244
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Basiliximab, Cyclosporine, Tacrolimus, Sirolimus, Methylprednisolone, Prednisone, Bactrim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 20 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
18
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 6, 2026, 10:46 PM EDT